Trial Profile
Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Refametinib (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- 24 Apr 2017 Status changed to completed.
- 30 Jan 2015 New trial record